BridgeBio Pharma (BBIO) Competitors $52.81 -0.69 (-1.29%) As of 01:10 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BBIO vs. ONC, INSM, BNTX, TEVA, SMMT, GMAB, ASND, VTRS, RDY, and QGENShould you be buying BridgeBio Pharma stock or one of its competitors? The main competitors of BridgeBio Pharma include BeOne Medicines (ONC), Insmed (INSM), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), and QIAGEN (QGEN). These companies are all part of the "pharmaceutical products" industry. BridgeBio Pharma vs. Its Competitors BeOne Medicines Insmed BioNTech Teva Pharmaceutical Industries Summit Therapeutics Genmab A/S Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories QIAGEN BridgeBio Pharma (NASDAQ:BBIO) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment. Do insiders & institutionals hold more shares of BBIO or ONC? 99.8% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 48.5% of BeOne Medicines shares are held by institutional investors. 18.2% of BridgeBio Pharma shares are held by company insiders. Comparatively, 6.6% of BeOne Medicines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is BBIO or ONC more profitable? BeOne Medicines has a net margin of -3.89% compared to BridgeBio Pharma's net margin of -329.25%. BridgeBio Pharma's return on equity of 0.00% beat BeOne Medicines' return on equity.Company Net Margins Return on Equity Return on Assets BridgeBio Pharma-329.25% N/A -85.69% BeOne Medicines -3.89%-1.22%-0.72% Do analysts recommend BBIO or ONC? BridgeBio Pharma currently has a consensus price target of $63.35, suggesting a potential upside of 19.51%. BeOne Medicines has a consensus price target of $330.89, suggesting a potential upside of 3.76%. Given BridgeBio Pharma's higher probable upside, equities research analysts plainly believe BridgeBio Pharma is more favorable than BeOne Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BridgeBio Pharma 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 3.00BeOne Medicines 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings and valuation, BBIO or ONC? BridgeBio Pharma has higher earnings, but lower revenue than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBridgeBio Pharma$235.81M42.97-$535.76M-$4.09-12.96BeOne Medicines$4.56B7.66-$644.79M-$1.73-184.34 Does the media refer more to BBIO or ONC? In the previous week, BridgeBio Pharma had 13 more articles in the media than BeOne Medicines. MarketBeat recorded 22 mentions for BridgeBio Pharma and 9 mentions for BeOne Medicines. BridgeBio Pharma's average media sentiment score of 1.05 beat BeOne Medicines' score of 0.04 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 14 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, BBIO or ONC? BridgeBio Pharma has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500. SummaryBridgeBio Pharma beats BeOne Medicines on 11 of the 15 factors compared between the two stocks. Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BBIO vs. The Competition Export to ExcelMetricBridgeBio PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.11B$4.42B$5.76B$10.07BDividend YieldN/A1.33%5.28%4.52%P/E Ratio-12.9311.1575.5226.24Price / Sales42.9716.34516.30171.25Price / CashN/A7.1337.2059.76Price / Book-6.883.3811.576.22Net Income-$535.76M-$134.23M$3.28B$270.65M7 Day Performance2.26%2.74%1.08%3.11%1 Month Performance13.80%14.89%11.26%9.04%1 Year Performance76.76%36.65%62.17%27.90% BridgeBio Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BBIOBridgeBio Pharma4.2248 of 5 stars$53.01-0.9%$63.35+19.5%+74.3%$10.11B$235.81M-12.93400Positive NewsInsider TradeONCBeOne Medicines1.2713 of 5 stars$346.45+1.4%$330.89-4.5%N/A$37.46B$3.81B0.0011,000Insider TradeGap UpINSMInsmed3.5043 of 5 stars$146.68+1.1%$139.86-4.7%+105.0%$30.67B$363.71M-25.691,271Positive NewsAnalyst ForecastBNTXBioNTech2.2296 of 5 stars$102.66-8.7%$135.80+32.3%+1.6%$27.04B$2.98B-64.166,772News CoverageAnalyst ForecastGap DownHigh Trading VolumeTEVATeva Pharmaceutical Industries3.3743 of 5 stars$19.30+1.8%$24.71+28.1%+10.6%$21.73B$16.54B-120.6136,830Positive NewsAnalyst RevisionSMMTSummit Therapeutics2.8428 of 5 stars$19.44-25.2%$33.79+73.8%-1.6%$19.30BN/A-19.25110News CoverageAnalyst ForecastGap DownHigh Trading VolumeGMABGenmab A/S4.0172 of 5 stars$27.54flat$37.60+36.5%+1.3%$17.67B$3.12B13.842,682News CoverageASNDAscendis Pharma A/S3.5476 of 5 stars$205.22-0.3%$244.36+19.1%+73.7%$12.60B$393.54M-39.771,017Positive NewsVTRSViatris1.7089 of 5 stars$10.48-0.2%$10.40-0.8%-6.1%$12.24B$14.74B-3.6132,000RDYDr. Reddy's Laboratories2.636 of 5 stars$14.27-0.5%$16.95+18.8%-8.2%$11.97B$3.81B21.6127,811Positive NewsQGENQIAGEN4.7074 of 5 stars$47.62+0.1%$49.69+4.4%+5.5%$10.57B$1.98B28.135,765Positive News Related Companies and Tools Related Companies BeOne Medicines Alternatives Insmed Alternatives BioNTech Alternatives Teva Pharmaceutical Industries Alternatives Summit Therapeutics Alternatives Genmab A/S Alternatives Ascendis Pharma A/S Alternatives Viatris Alternatives Dr. Reddy's Laboratories Alternatives QIAGEN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BBIO) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored6-Figure Target for BTC by 2025Trump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredTrump’s reported death a hoaxHow Trump’s latest policies could trigger a full-scale debt collapse… And the specific investments that cou...Porter & Company | SponsoredWorld War 3? Everything Just Changed — and One Tiny Company Is at the Center of It.Trump immediately activated a $5.3 TRILLION AI missile shield — code-named Golden Dome — to stop drone swarms ...Angel Publishing | SponsoredWall Street legend: “Put $1,000 in this AI stock”A massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
